HCA

HCA Healthcare, Inc. (HCA) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This summary covers the unaudited quarterly report (Form 10-Q) for HCA Healthcare, Inc. for the period ended March 31, 2026. HCA is a holding company whose affiliates own and operate 189 hospitals, 119 freestanding surgery centers, and 30 freestanding endoscopy centers across 19 U.S. states and England. The company operates in three geographic groups: National, Atlantic, and American.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 4.3% year-over-year, driven by a 1.1% increase in equivalent admissions and a 3.1% increase in revenue per equivalent admission.
• Profitability: Net income attributable to HCA rose 0.6% to $1.620 billion. The effective tax rate decreased to 18.8% (21.0% excluding noncontrolling interests) from 21.6% (23.8%) in the prior year, primarily due to increased deductible share-based compensation.
• Volume Trends: Consolidated admissions increased 0.7%. However, inpatient surgical volumes declined 0.4% and outpatient surgical volumes declined 2.7%. Emergency department visits declined 0.4%.
• Uninsured Admissions: Uninsured admissions increased significantly by 15.6% (consolidated) and 15.5% (same facility), attributed to the expiration of enhanced premium tax credits (EPTCs) at the end of 2025 and administrative reforms.
• Cost Structure: Salaries and benefits were 43.3% of revenue (down from 43.6%). Other operating expenses increased to 21.9% of revenue (from 21.0%) due to growth in state supplemental Medicaid program expenses and technology investments.

Guidance, Outlook, and Risks

• Capital Expenditures: Planned capital expenditures for 2026 are expected to be between $5.0 billion and $5.5 billion. Projects under construction have estimated additional costs of approximately $8.8 billion over the next five years.
• Share Repurchases: The company repurchased 3.157 million shares in Q1 2026 for approximately $1.571 billion. As of March 31, 2026, $9.179 billion of repurchase authorization remained available under the January 2026 program.
• Dividends: A quarterly dividend of $0.78 per share was declared on April 23, 2026, payable June 30, 2026.
• Key Risks:
  • Regulatory & Policy: Ongoing impact from the expiration of EPTCs and potential changes to Medicaid State Directed Payments (SDP) and supplemental programs.
  • Uncompensated Care: Estimated cost of total uncompensated care rose to $1,252 million in Q1 2026 from $1,055 million in Q1 2025.
  • Debt Service: Significant indebtedness with an average effective interest rate of 5.0% on long-term debt. Interest expense was $584 million.
  • Seasonality & Weather: Q1 volumes were impacted by a decrease in seasonal respiratory-related activity and a winter storm in certain markets.

Investor Verification Checklist

• Uninsured Patient Impact: Verify the sustainability of the 15.6% increase in uninsured admissions and its long-term effect on margins given the expiration of EPTCs.
• Medicaid Funding: Monitor the status of State Directed Payment (SDP) applications and potential grandfathering under the 2025 Federal Budget Act, as these could significantly impact future revenues.
• Debt Refinancing: Assess the company's ability to refinance $3.65 billion in commercial paper and manage interest rate exposure on variable-rate debt.
• Volume Mix: Analyze the decline in surgical volumes (inpatient -0.4%, outpatient -2.7%) to determine if this is a temporary seasonal/weather effect or a structural shift.
• Capital Allocation: Review the balance between $1.57 billion in share repurchases and $1.12 billion in capital expenditures against the $2.01 billion operating cash flow.